D. E. Shaw & Co. Inc. Acquires 1,534,666 Shares of Sotera Health (NASDAQ:SHC)

D. E. Shaw & Co. Inc. lifted its position in shares of Sotera Health (NASDAQ:SHC - Free Report) by 140.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,624,750 shares of the company's stock after purchasing an additional 1,534,666 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.93% of Sotera Health worth $35,907,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SHC. Barclays PLC boosted its position in shares of Sotera Health by 169.8% during the third quarter. Barclays PLC now owns 473,597 shares of the company's stock worth $7,909,000 after purchasing an additional 298,085 shares in the last quarter. GAMMA Investing LLC lifted its position in Sotera Health by 37.5% in the 4th quarter. GAMMA Investing LLC now owns 4,109 shares of the company's stock valued at $56,000 after acquiring an additional 1,121 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Sotera Health by 2.1% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 51,940 shares of the company's stock valued at $711,000 after acquiring an additional 1,047 shares in the last quarter. Oak Thistle LLC bought a new stake in Sotera Health in the 4th quarter valued at $222,000. Finally, SG Americas Securities LLC lifted its position in Sotera Health by 271.6% in the 4th quarter. SG Americas Securities LLC now owns 36,364 shares of the company's stock valued at $497,000 after acquiring an additional 26,577 shares in the last quarter. 91.03% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Piper Sandler lowered their price target on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and upped their price target for the stock from $14.00 to $17.00 in a report on Monday, May 5th. Finally, Barclays lowered their price objective on shares of Sotera Health from $16.00 to $12.00 and set an "overweight" rating for the company in a research report on Thursday, April 10th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $15.80.

Sotera Health Stock Up 0.6%

NASDAQ:SHC traded up $0.08 during trading hours on Friday, reaching $12.82. The company had a trading volume of 253,644 shares, compared to its average volume of 1,176,295. The company has a quick ratio of 2.61, a current ratio of 2.88 and a debt-to-equity ratio of 4.91. The firm has a market cap of $3.64 billion, a price-to-earnings ratio of 51.26 and a beta of 1.88. The business's 50-day simple moving average is $11.54 and its two-hundred day simple moving average is $12.88. Sotera Health has a twelve month low of $9.53 and a twelve month high of $17.08.

Sotera Health (NASDAQ:SHC - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The firm had revenue of $254.52 million for the quarter, compared to analyst estimates of $245.56 million. During the same period last year, the firm earned $0.13 earnings per share. The business's quarterly revenue was up 2.6% compared to the same quarter last year. On average, equities analysts expect that Sotera Health will post 0.61 earnings per share for the current year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.